XML 68 R63.htm IDEA: XBRL DOCUMENT v2.4.0.8
18. Pro Forma Financials for Acquisition of Canterbury, Hygeia, Paloma and VasculoMedics (Details) (USD $)
 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Revenues $ 0 $ 0
Cost of revenues 0 0
Gross margin 0 0
Operating expenses    
General and administrative 611,845 624,674
Warrants, options and stock compensation 149,885 1,316,148
Legal and professional services 131,686 143,103
Depreciation and amortization 478,104 8,687
Total operating expenses 1,371,520 2,092,612
Loss from operations (1,371,520) (2,092,612)
Other (income)/expenses    
Loss on adjustments to fair value of derivative liability 0 (236,850)
Other income (49,639) (2,564)
Interest expense 58,294 22,971
Total other expenses 8,655 257,257
Net loss from continuing operations (1,380,175) (2,349,869)
Net loss from discontinued operations 0 (126,911)
Net loss (1,380,175) (2,476,780)
Basic and diluted loss per share $ (0.23) $ (2.91)
Fully-diluted weighted average shares outstanding 5,934,474 1,207,534
RestorGenex
    
Revenues    [1]    [2]
Cost of revenues    [1]    [2]
Gross margin    [1]    [2]
Operating expenses    
General and administrative 611,845 [1] 624,674 [2]
Warrants, options and stock compensation 149,885 [1] 1,316,148 [2]
Legal and professional services 131,686 [1] 143,103 [2]
Depreciation and amortization 478,104 [1] 8,687 [2]
Total operating expenses 1,371,520 [1] 2,092,612 [2]
Loss from operations (1,371,520) [1] (2,092,612) [2]
Other (income)/expenses    
Loss on adjustments to fair value of derivative liability   236,850 [2]
Other income (49,639) [1] (2,564) [2]
Interest expense 58,294 [1] 22,971 [2]
Total other expenses 8,655 [1] 257,257 [2]
Net loss from continuing operations (1,380,175) [1] (2,349,869) [2]
Net loss from discontinued operations    [1] (126,911) [2]
Net loss (1,380,175) [1] (2,476,780) [2]
Basic and diluted loss per share $ (0.23) [1] $ (2.77) [2]
Basic weighted average shares outstanding 5,934,474 [1] 892,534 [2]
Fully-diluted weighted average shares outstanding   1,207,534 [2]
Paloma
    
Revenues    [1]    [2]
Cost of revenues    [1]    [2]
Gross margin    [1]    [2]
Operating expenses    
General and administrative 102,153 [1] 47,880 [2]
Legal and professional services 1,725 [1] 17,254 [2]
Depreciation and amortization 634 [1]  
Total operating expenses 104,512 [1] 65,134 [2]
Loss from operations (104,512) [1] (65,134) [2]
Other (income)/expenses    
Other income (25,397) [1] (63,910) [2]
Interest expense 29,925 [1] 20,781 [2]
Total other expenses 4,528 [1] (43,129) [2]
Net loss from continuing operations (109,040) [1] (22,005) [2]
Net loss from discontinued operations    [1]    [2]
Net loss (109,040) [1] (22,005) [2]
Basic and diluted loss per share    [1]    [2]
Basic weighted average shares outstanding 2,500,000 [1],[3] 2,500,000 [2],[4]
Fully-diluted weighted average shares outstanding   2,500,000 [2],[4]
VasculoMedics
    
Revenues    [1]    [2]
Cost of revenues    [1]    [2]
Gross margin    [1]    [2]
Operating expenses    
General and administrative    [1]    [2]
Warrants, options and stock compensation    [1]    [2]
Legal and professional services    [1]    [2]
Depreciation and amortization    [1]    [2]
Total operating expenses    [1]    [2]
Loss from operations    [1]    [2]
Other (income)/expenses    
Other income    [1]    [2]
Interest expense    [1]  
Total other expenses    [1]    [2]
Net loss from continuing operations    [1]    [2]
Net loss from discontinued operations    [1]    [2]
Net loss    [1]    [2]
Basic and diluted loss per share    [1]    [2]
Basic weighted average shares outstanding 220,000 [1],[3] 220,000 [2],[4]
Fully-diluted weighted average shares outstanding   220,000 [2],[4]
Pro Forma Adjustments
    
Revenues    [1]    [2]
Cost of revenues    [1]    [2]
Gross margin    [1]    [2]
Operating expenses    
General and administrative 81,250 [1],[5] 848,732 [2],[6]
Warrants, options and stock compensation    [1]    [2]
Legal and professional services    [1]    [2]
Depreciation and amortization 27,755 [1],[7] 687,713 [2],[8]
Total operating expenses 109,005 [1] 1,536,445 [2]
Loss from operations (109,005) [1] (1,536,445) [2]
Other (income)/expenses    
Other income    [1]    [2]
Interest expense    [1]    [2]
Total other expenses    [1]    [2]
Net loss from continuing operations (109,005) [1] (1,536,445) [2]
Net loss from discontinued operations    [1]    [2]
Net loss (109,005) [1] (1,536,445) [2]
Basic and diluted loss per share    [1]    [2]
Basic weighted average shares outstanding    [1]    [2]
Fully-diluted weighted average shares outstanding      [2]
Pro Forma Combined
    
Revenues    [1] 46,155 [2]
Cost of revenues    [1] 54,765 [2]
Gross margin    [1] (8,610) [2]
Operating expenses    
General and administrative 795,248 [1] 1,552,617 [2]
Warrants, options and stock compensation 149,885 [1] 1,316,148 [2]
Legal and professional services 133,411 [1] 185,792 [2]
Depreciation and amortization 506,493 [1] 700,612 [2]
Total operating expenses 1,585,037 [1] 3,755,169 [2]
Loss from operations (1,585,037) [1] (3,763,779) [2]
Other (income)/expenses    
Loss on adjustments to fair value of derivative liability   236,850
Other income (75,036) [1] (66,474) [2]
Interest expense 88,219 [1] 46,110 [2]
Total other expenses 13,183 [1] (216,486) [2]
Net loss from continuing operations (1,598,220) [1] (3,980,265) [2]
Net loss from discontinued operations    [1] (126,911) [2]
Net loss (1,598,220) [1] (4,107,176) [2]
Basic and diluted loss per share $ (0.18) [1] $ (0.86) [2]
Basic weighted average shares outstanding 8,654,474 [1] 4,762,650 [2]
Fully-diluted weighted average shares outstanding   5,077,650 [2]
Canterbury
    
Revenues   46,155 [2]
Cost of revenues   54,765 [2]
Gross margin   (8,610) [2]
Operating expenses    
General and administrative   31,331 [2]
Warrants, options and stock compensation      [2]
Legal and professional services   25,435 [2]
Depreciation and amortization   4,212 [2]
Total operating expenses   60,978 [2]
Loss from operations   (69,588) [2]
Other (income)/expenses    
Other income      [2]
Interest expense   2,358 [2]
Total other expenses   2,358 [2]
Net loss from continuing operations   (71,946) [2]
Net loss from discontinued operations      [2]
Net loss   (71,946) [2]
Basic and diluted loss per share      [2]
Basic weighted average shares outstanding   1,150,116 [2],[4]
Fully-diluted weighted average shares outstanding   1,150,116 [2],[4]
Hygeia
    
Revenues      [2]
Cost of revenues      [2]
Gross margin      [2]
Operating expenses    
General and administrative      [2]
Warrants, options and stock compensation      [2]
Legal and professional services      [2]
Depreciation and amortization      [2]
Total operating expenses      [2]
Loss from operations      [2]
Other (income)/expenses    
Other income      [2]
Total other expenses      [2]
Net loss from continuing operations      [2]
Net loss from discontinued operations      [2]
Net loss      [2]
Basic and diluted loss per share      [2]
Basic weighted average shares outstanding      [2]
Fully-diluted weighted average shares outstanding      [2]
[1] Assumes the mergers with Paloma and VasculoMedics occurred on January 1, 2014.
[2] Assumes the mergers with Canterbury, Hygeia, Paloma and VasculoMedics occurred on January 1, 2013.
[3] Impact on weighted average shares outstanding for the acquisition shares being outstanding for the entire quarter.
[4] Impact on weighted average shares if the 1,150,116 shares issued for the mergers with Canterbury and Hygeia, the 2,500,000 shares issued for the Paloma merger and the 220,000 shares issued for the VasculoMedics merger were outstanding for the quarter.
[5] Impact of employment agreements from January 1, 2014 to March 31, 2014.
[6] Adds the $848,732 of expenses associated with employment agreements for Canterbury and Paloma executives that would be incurred from January 1, 2013.
[7] Amortization of intangible assets for Paloma assuming a 20-year amortization period.
[8] Adds $659,958 of additional amortization for intangible assets at Canterbury and $27,755 for Paloma (assuming at 20-year amortization period) that would be incurred if amortization began on January 1, 2013.